Alexion Pharmaceuticals (ALXN) : Alexion Pharmaceuticals (ALXN) had a healthy money flow of $4.29 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $21.75 million, whereas, investors only sold shares worth $17.45 million on downticks. The stock closed the day with an up-down ratio of 1.25.The money flow in the block trades to the tune of $3.13 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $3.13 million worth of transactions were on upticks. Alexion Pharmaceuticals (ALXN) stock slid $0.02 intraday and traded at 125.56, a change of -0.02% over previous days close. However, for the week, the company shares are 0.92% compared to previous weeks close.
Alexion Pharmaceuticals, Inc. has dropped 19.43% during the last 3-month period . Year-to-Date the stock performance stands at -34.23%. Shares of Alexion Pharmaceuticals, Inc. appreciated by 0.13% during the last five trading days but lost 1.59% on a 4-week basis. In a related news, The Securities and Exchange Commission has divulged that Moriarty John B, officer (EVP & General Counsel) of Alexion Pharmaceuticals Inc, had unloaded 918 shares at an average price of $135.72 in a transaction dated on June 13, 2016. The total value of the transaction was worth $124,591.
Alexion Pharmaceuticals (NASDAQ:ALXN): On Mondays trading session , Opening price of the stock was $125.62 with an intraday high of $125.98. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $124.001. However, the stock managed to close at $125.46, a loss of 0.10% for the day. On the previous day, the stock had closed at $125.58. The total traded volume of the day was 1,003,101 shares.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.